The impact of COVID-19 on opioid treatment program (OTP) services: Where do we go from here?

被引:12
|
作者
Tracy, Kathlene [1 ,2 ,3 ]
Wachtel, Leah [1 ]
Friedman, Teri [4 ,5 ]
机构
[1] Icahn Sch Med Mt Sinai, Dept Psychiat, Lab Psychosocial Proc Addict, 1399 Pk Ave, New York, NY 10029 USA
[2] Addict Inst Mt Sinai AIMS, Psychosocial Div, 1470 Madison Ave, New York, NY 10029 USA
[3] Friedman Brain Inst FBI, 1470 Madison Ave, New York, NY 10029 USA
[4] Mt Sinai Beth Israel, Opioid Treatment Program, 103 E 125th St,3rd Floor, New York, NY 10025 USA
[5] New York State Coalit Medicat Assisted Treatment, 121 West 36th St,201, New York, NY 10018 USA
关键词
COVID-19; Opioid use disorder; Addiction services; Medication for opioid use disorders; Methadone;
D O I
10.1016/j.jsat.2021.108394
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Medication for opioid use disorder (MOUD) services is key to addressing the opioid crisis and COVID-19 has significantly impacted MOUD delivery. The need for social distancing and self-quarantining requires individuals to maintain personal physical space and limits face-to-face interactions, which are required for methadone dispensing and other regulated treatment activities. Mount Sinai Beth Israel, which has one of the largest opioid treatment service (OTP) delivery systems within the United States and included 10 OTP methadone clinics that responded rapidly by implementing procedures to address the additional challenges during the COVID-19 pandemic. This article discusses four key procedural areas: 1) verified identity in-person pick-up doses, 2) drug urine toxicology screens, 3) treatment interactions, and 4) discharges, which can inform future OTP operational procedures by encouraging out-of-the-box thinking in this new age.
引用
收藏
页数:3
相关论文
共 50 条
  • [1] COVID-19: where do we go from here?
    Lancet, The
    LANCET, 2021, 398 (10318): : 2207 - 2207
  • [2] Science during COVID-19: where do we go from here?
    不详
    LANCET, 2020, 396 (10267): : 1941 - 1941
  • [3] Teacher stress and COVID-19: Where do we go from here?
    McCarthy, Christopher J.
    Blaydes, Madison
    Weppner, Caroline H.
    Lambert, Richard G.
    PHI DELTA KAPPAN, 2022, 104 (01) : 12 - 17
  • [5] The Impact of the COVID-19 Pandemic on Radiology Resident Education: Where Do We Go From Here?
    Patil, Nikhil S.
    Gunter, Dane
    Larocque, Natasha
    ACADEMIC RADIOLOGY, 2022, 29 (04) : 576 - 583
  • [6] COVID-19-where do we go from here?
    Lee, Pei Hua
    Vasoo, Shawn
    SINGAPORE MEDICAL JOURNAL, 2020, 61 (07) : 343 - 344
  • [7] Cancer Research after COVID-19: Where Do We Go from Here?
    Colbert, Lauren E.
    Kouzy, Ramez
    Jaoude, Joseph Abi
    Ludmir, Ethan B.
    Taniguchi, Cullen M.
    CANCER CELL, 2020, 37 (05) : 637 - 638
  • [8] The Impact of COVID-19 on Physical Activity and Related Health Outcomes: Where Do We Go from Here?
    Stevens, Emily C.
    Gallo, Paul M.
    Dyer, Jaimy M.
    Balk, Ethan K.
    HEALTH BEHAVIOR AND POLICY REVIEW, 2023, 10 (02): : 1218 - 1229
  • [9] COVID-19 imaging, where do we go from here? Bibliometric analysis of medical imaging in COVID-19
    Ru Wen
    Mudan Zhang
    Rui Xu
    Yingming Gao
    Lin Liu
    Hui Chen
    Xingang Wang
    Wenyan Zhu
    Huafang Lin
    Chen Liu
    Xianchun Zeng
    European Radiology, 2023, 33 : 3133 - 3143
  • [10] The COVID-19 Pandemic and Sexually Transmitted Infections: Where Do We Go From Here?
    Rogers, Brooke
    Tao, Jun
    Murphy, Matthew
    Chan, Philip A.
    SEXUALLY TRANSMITTED DISEASES, 2021, 48 (07) : E94 - E96